When was First Wave Bio founded?

First Wave Bio was founded in 2015 and raised its 1st funding round 4 years after it was founded.

Where is First Wave Bio located?

First Wave Bio is headquartered in Ann Arbor, United States.

Who is the current CEO of First Wave Bio?

Gary D Glick of First Wave Bio. They have also founded 1 company.

How many employees does First Wave Bio have?

As of Mar 31, 2026, the latest employee count at First Wave Bio is 5.

Is First Wave Bio a funded company?

First Wave Bio is a funded company, having raised an undisclosed amount across 3 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Aug 19, 2019.

How much is First Wave Bio worth?

The last known valuation of First Wave Bio was $***** as of Sep 13, 2021.

When was the latest funding round of First Wave Bio?

First Wave Bio's latest funding was a $***** Post IPO round on Dec 27, 2023, with participation from 0 investor. Its primary sector is Gastroenterology. In United States, the Gastroenterology sector has seen $604M in funding in 2026 to date.

Where does First Wave Bio rank among its competitors?

First Wave Bio ranks 749th amongst 2555 active competitors, of which 861 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of First Wave Bio?

First Wave Bio's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

First Wave Bio - 2026 Company Profile, Team, Funding, Competitors & Financials

First Wave Bio is an acquired company based in Ann Arbor (United States), founded in 2015 by Anthony W Opipari, Gary D Glick and Luigi Franchi. It operates as a Developer of therapeutics for treating inflammatory bowel disease. First Wave Bio has raised an undisclosed amount in funding, with last known valuation of $*****. The company has 2555 active competitors, including 861 funded and 644 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Developer of therapeutics for treating inflammatory bowel disease. The company is developing different proprietary forms and formulations of the gut-restricted salicylanilide antihelmintic drug called Niclosamide. The lead candidate is FW-424 which is used to target pathogenic immune cells in IBD.

Website: firstwavebio.com
Email ID: *****@firstwavebio.com
Phone Number: +1 **********

Key Metrics

Founded Year

2015

Location

Ann Arbor, United States

Stage

Acquired

Latest Funding Round

Post IPO, Dec 27, 2023, $*****

Last Known Valuation

$***** as on Sep 13, 2021

Investors

Abingworth & 2 more

Ranked

749^th among 2555 active competitors

Employee Count

5 as on Mar 31, 2026

Similar Companies

Ironwood Pharma & 154 more

Exit Details

Acquired by AzurRx BioPharma (Sep 13, 2021)

View First Wave Bio's full profile

First Wave Bio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
FIRST WAVE BIOPHARMA, INC. CIN: 1604191 , United States, Active	Apr 01, 2014	-	-	-

First Wave Bio got acquired by AzurRx BioPharma on Sep 13, 2021.

Click here to take a look at First Wave Bio's acquisition in detail

First Wave Bio has raised funding over 3 rounds. Its first funding round was on Aug 19, 2019. First Wave Bio has 3 institutional investors.

Here is the list of recent funding rounds of First Wave Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 27, 2023	4873711	Post IPO	3850518	2859910	1049663	2897330
Jul 15, 2022	3172110	Post IPO	4370276	1237752	9713651	7745900
Aug 19, 2019	6632889	Post IPO	6680821	1961905	1730904	7538673

Access funding benchmarks and valuations. Sign up today!

View details of First Wave Bio's funding rounds and investors

The founders of First Wave Bio are Anthony W Opipari, Gary D Glick and Luigi Franchi. Gary D Glick is the CEO of First Wave Bio.

Here are the details of First Wave Bio's key team members:

Anthony W Opipari: Co-Founder of First Wave Bio.
Gary D Glick: Co-Founder & CEO of First Wave Bio.
Luigi Franchi: Co-Founder of First Wave Bio.

View details of First Wave Bio's Founder profiles and Board Members

First Wave Bio's employee count trend

First Wave Bio has 5 employees as of Mar 26. Here is First Wave Bio's employee count trend over the years:

Uncover First Wave Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of First Wave Bio include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of First Wave Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	71/100
10th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
749th	First Wave Bio 2015, Ann Arbor (United States), Acquired	Developer of therapeutics for treating inflammatory bowel disease	-	Abingworth, Omega Funds & 1 others	41/100